Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Clearside Biomedical (Nasdaq: CLSD), a company specializing in suprachoroidal space (SCS®) therapy delivery to the back of the eye, has announced its participation in the Stifel 2024 Healthcare Conference. George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of R&D, will engage in a fireside chat on November 19, 2024, at 8:00 a.m. ET in New York.
The event will be accessible via webcast on Clearside's website under the Investors section, with the recording remaining available for three months following the presentation.
Clearside Biomedical (Nasdaq: CLSD), un'azienda specializzata nella somministrazione di terapie nello spazio suprachoroidale (SCS®) verso la parte posteriore dell'occhio, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. George Lasezkay, Presidente e CEO, e Victor Chong, Direttore Medico e EVP di Ricerca e Sviluppo, parteciperanno a una conversazione informale il 19 novembre 2024, alle 8:00 a.m. ET a New York.
L'evento sarà accessibile tramite webcast sul sito web di Clearside nella sezione dedicata agli Investitori, con la registrazione che rimarrà disponibile per tre mesi dopo la presentazione.
Clearside Biomedical (Nasdaq: CLSD), una empresa especializada en la entrega de terapia en el espacio suprachoroidal (SCS®) en la parte posterior del ojo, ha anunciado su participación en la Stifel 2024 Healthcare Conference. George Lasezkay, Presidente y CEO, y Victor Chong, Oficial Médico Principal y EVP de I+D, participarán en una charla informal el 19 de noviembre de 2024, a las 8:00 a.m. ET en Nueva York.
El evento será accesible a través de un webcast en el sitio web de Clearside en la sección de Inversores, con la grabación disponible durante tres meses después de la presentación.
Clearside Biomedical (Nasdaq: CLSD), 눈 뒤쪽에 있는 suprachoroidal space (SCS®) 치료 전달을 전문으로 하는 회사가 Stifel 2024 Healthcare Conference에 참여한다고 발표했습니다. George Lasezkay, 사장 겸 CEO, Victor Chong, 최고 의료 책임자 및 R&D EVP가 2024년 11월 19일, 오전 8시 ET에 뉴욕에서 진행되는 화상 대화에 참여할 것입니다.
이벤트는 Clearside의 웹사이트 투자자 섹션에서 웹캐스트를 통해 접근할 수 있으며, 발표 후 3개월 동안 녹화본이 제공됩니다.
Clearside Biomedical (Nasdaq: CLSD), une entreprise spécialisée dans l'administration de thérapies dans l'espace suprachoroïdal (SCS®) vers l'arrière de l'œil, a annoncé sa participation à la Stifel 2024 Healthcare Conference. George Lasezkay, Président et PDG, et Victor Chong, Médecin Chef et EVP de la R&D, participeront à une discussion informelle le 19 novembre 2024, à 8h00 ET à New York.
L'événement sera accessible par webcast sur le site de Clearside dans la section investisseurs, avec l'enregistrement disponible pendant trois mois après la présentation.
Clearside Biomedical (Nasdaq: CLSD), ein Unternehmen, das sich auf die Abgabe von Therapien im suprachoroidalen Raum (SCS®) zur Hinterseite des Auges spezialisiert hat, hat seine Teilnahme an der Stifel 2024 Healthcare Conference angekündigt. George Lasezkay, Präsident und CEO, sowie Victor Chong, Chief Medical Officer und EVP für Forschung und Entwicklung, werden am 19. November 2024, um 8:00 Uhr ET in New York an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird über einen Webcast auf der Website von Clearside im Bereich Investoren zugänglich sein, und die Aufzeichnung bleibt drei Monate nach der Präsentation verfügbar.
- None.
- None.
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET in New York, NY.
A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), recently completed a Phase 2b clinical trial, and planning for a Phase 3 program is underway. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
When is Clearside Biomedical (CLSD) presenting at the Stifel 2024 Healthcare Conference?
Who will represent Clearside Biomedical (CLSD) at the Stifel 2024 Healthcare Conference?
How can investors access Clearside Biomedical's (CLSD) presentation at the Stifel conference?
What is Clearside Biomedical's (CLSD) main focus in drug delivery?
